VelosBio to be Acquired by Merck…

 
SAN DIEGO, May 14, 2009 /PRNewswire/ — TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009.